{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Change', 'Sections Changed', 'Increased the duration of which the investigator is', 'Section 9.4.3 Other Events that Require', 'required to report a pregnancy, from \"within 90', 'Accelerated Reporting to Sponsor', 'days\\' to \"within 6 months,\\' of the last dose of', 'study drug. This change was made to ensure', 'consistency with Exclusion criterion #16', '(Section 6.2.2) to exclude women of childbearing', 'potential who are unwilling to practice highly', 'effective contraception for at least 6 months after', 'the last dose of study drug.', 'Added the description of patient population, to the', 'Section 6.2 Study Population', 'appropriate section in the protocol body, for', 'consistency with the corresponding section in the', 'Clinical Study Protocol Synopsis', 'Added clarification that for patients who', 'Section 8.4.3 Irinotecan Dose', 'experience toxicity with a dose increase from', 'Modifications', '100 mg/m\u00b2 to 125 mg/m\u00b2, the recommended first', 'dose reduction should be to 100 mg/m\u00b2.', 'Added clarification of the Dose Modification and', 'Section 8.4 Dose Modification and Study', 'Study Treatment Discontinuation Rules for', 'Treatment Discontinuation Rules for', \"Investigator's Choice Chemotherapy that for other\", \"Investigator's Choice Chemotherapy\", 'chemotherapy-related AEs that are not', 'specifically addressed in these sections, the', 'general approach for > grade 3 treatment-related', 'AEs is to hold chemotherapy until resolution of', 'the event to VI grade 1 or baseline, and to reduce', 'by one dose level on resumption of treatment.', 'Added language regarding selection of', 'Section 8.1 Investigational and Reference', \"Investigator's Choice Chemotherapy when\", 'Treatments', 'prescribing chemotherapy to patients on the', 'control arm to give preference to regimens', 'allowed by local regulations. This addition was', 'requested by the', 'Added clarification that the EORTC QLQ-C30', 'Table 1: Schedule of Events: Screening', 'assessment may be performed at any subsequent', 'and Treatment Period', 'visit if the assessment is not performed on day 1.', 'Section 7.1.2 Footnotes for the Schedule', 'of Events Table for Screening and', 'Treatment - Footnote #14', 'Added a subgroup analysis by number of prior', 'Section 10.4.5.5 Subgroup Analysis', 'lines of systemic therapy for recurrent or', 'metastatic disease (1 line or >1 line), which will', 'Regeneron Pharmaceuticals, Inc.', 'Page 10 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Change', 'Sections Changed', 'be performed for the primary and key secondary', 'endpoints. This planned analysis was in response', 'to a request by the Independent Data Monitoring', 'Committee.', 'Regeneron Pharmaceuticals, Inc.', 'Page 11 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Change', 'Sections Changed', 'Updated synopsis for consistency with', 'Clinical Study Protocol Synopsis -', 'Amendment 3 Japan, with addition of \"for', 'Treatments', 'patients enrolling in Japan, there will be at least', '14 days of rest before subsequent irinotecan', 'administration.', 'Removed details on drug supply packaging and', 'Section 8.1.1 Experimental Group', 'withdrawable volume and referred to the', 'Treatment (REGN2810 [Cemiplimab])', 'pharmacy manual', 'Added clarification that laboratory assessment of', 'Section 7.2.5.4 Laboratory Testing', 'glucose may be performed either fasting or non-', 'fasting', 'Clarified that the treatment days for gemcitabine', 'Section 8.4.4 Gemcitabine Dose', 'dose reduction guidelines for myelosuppression', 'Modifications', 'refer to a 3-week treatment cycle', 'Revised text to simply state that Exclusion', 'Section 6.2.2. Exclusion Criteria -', 'Criterion #10 was deleted in Amendment 3', 'Criterion #10', 'Removed placeholder for footnote 1 of Table 1,', 'Section 7.1.2 Footnotes for the Schedule', 'which was deleted in Amendment 3', 'of Events Table for Screening and', 'Treatment- footnote 1 (deleted)', 'Editorial revisions and corrections', 'Clinical Study Protocol Synopsis - Site', 'Locations', 'Section 3.2.2 Rationale for REGN2810', '(Cemiplimab) Dose Selection', 'Section 4.2.3 Other Secondary Endpoints', 'Section 6.1 Number of Patients Planned', 'Section 6.2.1 Inclusion Criteria -', 'Criterion #3', 'Section 7.2.5.4 Laboratory Testing', 'Section 8.1 Investigational and Reference', 'Treatments', 'Section 8.8 Method of Treatment', 'Assignment', 'Regeneron Pharmaceuticals, Inc.', 'Page 12 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}